Proximagen parcels out risk but retains rights - Proximagen parcels out risk but retains rights Neuro-degenerative disease specialist receives $26m investment from large pharmaceutical partners but keeps rights to European drugs Source: Pharmaceuticals companies news from the Financial Times Psychology, Special Needs & Health.